Mousa Aya, Flanagan Madeline, Tay Chau Thien, Norman Robert J, Costello Michael, Li Wentao, Wang Rui, Teede Helena, Mol Ben W
Monash Centre for Health Research and Implementation (MCHRI), Faculty of Medicine, Nursing and Health Sciences, Monash University, Victoria, Australia.
Department of Obstetrics and Gynaecology, Monash University, Victoria, Australia.
EClinicalMedicine. 2024 Jul 16;74:102717. doi: 10.1016/j.eclinm.2024.102717. eCollection 2024 Aug.
Clinical guidelines rely on sound evidence to underpin recommendations for patient care. Compromised research integrity can erode public trust and the credibility of the scientific enterprise, with potential harm to patients. Despite increased recognition of integrity concerns in scientific literature, there are no processes or guidance for incorporating integrity assessments into evidence-based guideline development or evidence synthesis more broadly.
In response to this crucial gap, we developed the esearch ntegrity in uidelines and evence synthesis (RIGID) framework. Co-developed with international input from 80 multidisciplinary experts, and consumers, the RIGID framework and accompanying checklist provide an innovative and transparent six-step approach to assess the integrity of studies during the synthesis of evidence, including in the development of clinical guidelines. Central to the framework is an integrity committee, responsible for objective assessments and allocations, with constructive author engagement.
The six key steps of the RIGID framework are described, as follows: (1) Review: standard systematic review processes are followed, in line with approved evidence synthesis methodologies; (2) Exclude: studies which have been retracted are excluded, and those with expressions of concern are flagged for further evaluation; (3) Assess: remaining studies are assessed for integrity using an appropriate tool and allocated an initial integrity risk rating of low, moderate or high risk for integrity concerns; (4) Discuss: integrity assessment results are discussed among integrity committee members with votes to determine final integrity risk rating allocations for each study; (5) Establish contact: low risk studies are included without author contact, whereas authors of studies ranked as moderate or high risk are contacted for clarification; (6) Reassess: studies are reassessed for inclusion using the RIGID author response algorithm (reclassified as 'included' where authors have provided a satisfactory response, 'awaiting classification' where authors have engaged but time is needed to address concerns, or 'not included' where authors have not responded to contact attempts). An illustrative case study is presented, where these six steps of the RIGID framework were successfully implemented in an influential international guideline endorsed by 39 societies across six continents. Following implementation of the framework, 45 of the 101 originally identified studies (45%) were not included in the guideline.
Based on the latest literature and international expertise, the RIGID framework represents an important advancement in best practice standards for guideline development and evidence synthesis. Using this resource, guideline developers, policy-makers, clinicians and scientists are better positioned to navigate the currently precarious research landscape to ensure evidence synthesis and subsequent clinical recommendations prioritize patient care and preserve the sanctity of scientific endeavors.
This study received no specific funding. The guideline in which it was piloted was supported by the Australian National Health and Medical Research Council (NHMRC) for guideline development through the Centre of Research Excellence (CRE) in Women's Health in Reproductive Life (CRE-WHiRL) (APP1171592) and the CRE in Polycystic Ovary Syndrome (CRE-PCOS) (APP1078444) led by Monash University, Australia, and partner societies: the American Society for Reproductive Medicine (ASRM), the US Endocrine Society (ENDO), the European Society of Endocrinology (ESE) and the European Society of Human Reproduction and Embryology (ESHRE).
临床指南依赖可靠的证据来支持针对患者护理的建议。研究诚信受损会侵蚀公众信任和科学事业的可信度,对患者可能造成伤害。尽管科学文献中对诚信问题的认识有所提高,但对于将诚信评估更广泛地纳入循证指南制定或证据综合过程中,尚无相关流程或指导。
针对这一关键差距,我们开发了指南与证据综合中的研究诚信(RIGID)框架。该框架由80位多学科专家和消费者提供国际意见共同开发而成,RIGID框架及随附清单提供了一种创新且透明的六步方法,用于在证据综合过程中评估研究的诚信度,包括在临床指南制定过程中。该框架的核心是一个诚信委员会,负责进行客观评估和分配,并与作者进行建设性互动。
RIGID框架的六个关键步骤如下所述:(1)审查:遵循标准的系统评价流程,符合经批准的证据综合方法;(2)排除:排除已撤回的研究,对存在关注声明的研究进行标记以便进一步评估;(3)评估:使用适当工具对剩余研究的诚信度进行评估,并为每项研究分配初始诚信风险评级,分为低、中、高风险;(4)讨论:诚信委员会成员讨论诚信评估结果,并进行投票以确定每项研究的最终诚信风险评级;(5)建立联系:低风险研究无需与作者联系即可纳入,而对于评级为中或高风险的研究作者,则需联系以进行澄清;(6)重新评估:使用RIGID作者回复算法对研究进行重新评估以确定是否纳入(若作者提供了令人满意的回复则重新分类为“纳入”,若作者已参与但需要时间解决问题则为“等待分类”,若作者未对联系尝试做出回应则为“不纳入”)。本文展示了一个案例研究,其中RIGID框架的这六个步骤在一项由六大洲39个学会认可的有影响力的国际指南中成功实施。在实施该框架后,最初确定的101项研究中有45项(45%)未被纳入该指南。
基于最新文献和国际专业知识,RIGID框架代表了指南制定和证据综合最佳实践标准的一项重要进展。利用这一资源,指南制定者、政策制定者、临床医生和科学家能够更好地应对当前不稳定的研究环境,以确保证据综合及后续临床建议将患者护理放在首位,并维护科学事业的神圣性。
本研究未获得特定资金。进行试点的指南由澳大利亚国家卫生与医学研究委员会(NHMRC)通过澳大利亚莫纳什大学领导的生殖生命期女性健康卓越研究中心(CRE - WHiRL)(APP1171592)和多囊卵巢综合征卓越研究中心(CRE - PCOS)(APP1078444)以及合作学会:美国生殖医学学会(ASRM)、美国内分泌学会(ENDO)、欧洲内分泌学会(ESE)和欧洲人类生殖与胚胎学会(ESHRE)提供指南制定支持。